@catreaamcknight's GLP-1 weight loss claims, fact-checked

What does this video actually claim?

Catrea McKnight's TikTok promotes Mochi Health, a telehealth platform offering GLP-1 medications for weight loss. She suggests these drugs can help with PCOS and encourages viewers to ignore others' opinions about their health decisions.

The video doesn't make specific medical claims about GLP-1 effectiveness or safety. Instead, it's a straightforward sponsored post promoting access to these medications through a telehealth service. McKnight mentions PCOS in her hashtags, implying these drugs might help with the condition.

She offers a $40 discount through her affiliate link. The post targets people who might be hesitant about starting weight loss medication due to social stigma or judgment from others.

Does the science support GLP-1s for weight loss?

The evidence for GLP-1 receptor agonists in weight management is solid. The STEP 1 trial (Wilding et al., NEJM, 2021) found that semaglutide 2.4mg led to 14.9% body weight loss over 68 weeks compared to 2.4% with placebo.

For tirzepatide, the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed even better results. Participants lost 15.0% of body weight with the 5mg dose and 20.9% with the 15mg dose over 72 weeks.

These aren't marginal improvements. We're talking about weight loss comparable to bariatric surgery for many patients. The FDA approved both semaglutide (Wegovy) and tirzepatide (Zepbound) for chronic weight management based on these results.

What about GLP-1s for PCOS specifically?

McKnight's PCOS hashtag raises questions about off-label use. While GLP-1s aren't FDA-approved specifically for PCOS, there's emerging evidence they might help with some symptoms.

A 2022 systematic review (Elkind-Hirsch et al., Endocrine Practice) found that liraglutide improved insulin resistance and menstrual regularity in women with PCOS. Weight loss was modest at 4-7kg over 12-26 weeks, less dramatic than obesity trials.

The connection makes biological sense. Many women with PCOS have insulin resistance, and GLP-1s improve glucose metabolism. Weight loss can also help restore ovulation and reduce androgen levels.

But calling this an established PCOS treatment would be premature. Most studies are small, and we need longer-term data on reproductive outcomes.

Is telehealth the right way to get these medications?

This is where things get complicated. GLP-1s require careful medical supervision, especially during the initial titration period. Starting doses are typically 0.25mg weekly for semaglutide, gradually increasing to 2.4mg over 16-20 weeks.

Telehealth platforms like Mochi Health can provide legitimate access to these medications. Many patients struggle to get appointments with endocrinologists or find doctors willing to prescribe weight loss medications.

However, proper screening matters. These drugs aren't suitable for people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. They can cause serious gastrointestinal side effects that require monitoring.

The question isn't whether telehealth is appropriate, but whether specific platforms provide adequate medical oversight. McKnight's post doesn't address the medical evaluation process, which would be helpful context for viewers.

What should you actually know about starting GLP-1s?

McKnight's advice to ignore other people's opinions about your health decisions has merit. Weight bias is real, and many people face judgment when seeking obesity treatment.

But the decision to start GLP-1 therapy shouldn't be driven by social media promotion or discount codes. These are powerful medications with real side effects, including nausea, vomiting, and potential pancreatitis.

Cost is also a major factor McKnight doesn't mention. Without insurance coverage, these medications can cost $900-1,200 monthly. Many insurance plans don't cover them for weight loss, even when medically appropriate.

The weight loss maintenance question remains open too. Most studies show weight regain when people stop these medications, suggesting they're likely lifelong treatments for many patients.